CAM
SPRY icon

ClariVest Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

ClariVest Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$2.45M Hold
287,596
– – 0.25% 103
2024
Q2 		$2.45M Buy
287,596
+14,640
+5% +$130K 0.25% 103
2024
Q1 		$2.79M Buy
+272,956
New +$2.04M 0.29% 90

Other funds holding SPRY

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

ClariVest Asset Management's SPRY Position: Q3 2024 in Review

ClariVest Asset Management held its ARS Pharmaceuticals (SPRY) position steady in Q3 2024 at 287,596 shares worth $2.45M. The position accounts for 0.25% of the portfolio, ranked #103.

ClariVest Asset Management first reported a position in SPRY in Q1 2024 and has held it in 3 quarters since. The position peaked at $2.79M in Q1 2024. 151 funds tracked by Wall St. Rank hold SPRY as of Q3 2024.

  • ClariVest Asset Management held 287,596 shares of ARS Pharmaceuticals worth $2.45M as of Q3 2024.
  • ClariVest Asset Management left its ARS Pharmaceuticals share count unchanged in Q3 2024.
  • ARS Pharmaceuticals made up 0.25% of ClariVest Asset Management's portfolio in Q3 2024, its #103 holding.
  • ClariVest Asset Management first reported a position in ARS Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • ClariVest Asset Management's ARS Pharmaceuticals position peaked at $2.79M in Q1 2024.
  • 151 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.